UNSPSC 51161513: Diprophylline or dyphylline

This classification denotes a phosphodiesterase inhibitor and bronchodilator with the molecular formula C10H14N4O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 263T0E9RR9, chemically known as 1,3-dimethyl-7-(2,3-dihydroxypropyl)xanthine but generally known as diprophylline, which bears US NIH Compound Identifier 3182. European Medicines Agency schedules Diprophylline in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07225MIG. The term DIPROPHYLLINE is an International Non-Proprietary Name.

UNSPSC 51161513 Diprophylline or dyphylline is a Commodity code describing a single active pharmaceutical ingredient used in respiratory and bronchial medications. State and local governments procure diprophylline primarily through multistate cooperative purchasing agreements that aggregate demand across participating agencies' health systems, correctional facilities, and public health departments. The scope of work involves manufacturers supplying the drug under National Drug Codes (NDCs) to authorized pharmaceutical wholesalers for distribution to member facilities, with vendors meeting current Good Manufacturing Practices (cGMP) and Drug Supply Chain Security Act (DSCSA) compliance. Issuing bodies include state purchasing offices administering cooperative purchasing vehicles; the Minnesota Department of Administration's Office of State Procurement represents the administrative lead for multistate contracts covering member states including Oregon and other participating jurisdictions.

The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) issued an RFP in January 2026 for Generic Multi Source Pharmaceuticals and OTC Products with a March 26, 2026 response deadline, establishing a two-year contract effective July 1, 2026, with optional extensions. Vendors must maintain relationships with at least two of three authorized wholesalers (AmerisourceBergen Drug Corporation / Cencora, Cardinal Health 110 and 112, and Morris & Dickson Co., LLC), offer flexible pricing structures (flat price, net price formats, or WAC-minus models), and carry insurance including $5 million commercial general liability and $2 million network security and privacy liability. Price competitiveness weighted at 75 percent of evaluation criteria, with administrative compliance and EDI capability comprising the remainder. Vendors pay a 3 percent administrative fee on all contract purchases and face performance penalties of $200 to $1,500 per violation for late reporting, missed onboarding, or improper class-of-trade denials. No specific set-aside designations are identified in the solicitation materials.